Lupus Mastitis in the Male Breast Mimicking Inflammatory Carcinoma

Fernández-Flores, Ángel; Crespo, Luis G.; Alonso, Soledad; Montero, Manuel G

doi:10.1111/j.1075-122x.2006.00256.x

Cited by 13 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7,10 Immunohistochemistry has been occasionally performed on these lesions primarily to exclude the possibility of a low-grade lymphoma. Results have shown a mixed population of CD20 + B-lymphocytes and predominantly CD3 + and CD4 + T-lymphocytes 8,12,14 with polyclonal plasma cells. 8 These are concordant with the results from case 1 in this article.…”

Section: Discussionmentioning

confidence: 98%

“…8 These are concordant with the results from case 1 in this article. In one report, polymerase chain reaction was performed showing polyclonal rearrangement of IgH and T-cell receptor-g. 12 In general, the histologic findings of LP are considered sufficiently diagnostic to allow for an accurate diagnosis. Clinical history of lupus and the presence of overlying epidermal and dermal changes of lupus are also helpful diagnostically.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Lupus Mastitis

Kinonen

Gattuso

Reddy

2010

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Lupus mastitis is an uncommon presentation of lupus erythematosus profundus or lupus panniculitis, a rare variant of lupus erythematosus characterized by inflammation of the subcutaneous fat. Lupus mastitis can present as single or multiple subcutaneous or deep breast masses, often clinically mimicking malignancy. Although lupus mastitis is rare, with less than 25 cases reported, the histologic features are distinct. Awareness of the entity and familiarity with the histologic features allow for accurate diagnosis and appropriate patient management. It most commonly affects women with a mean age at diagnosis of 40 years and an age range of 18 to 70 years. Typical histologic findings in lupus mastitis include a lymphocytic lobular panniculitis with plasma cells and hyaline fat necrosis. The lymphocytic infiltrate can be nodular, diffuse, periductal, and/or perilobular and germinal centers can frequently be identified. Lymphocytic vasculitis is also common. Immunohistochemistry shows a mixed T and B-cell population, with predominantly CD3+ CD4+ T cells intermixed with CD20-positive B cells and polyclonal plasma cells. Most commonly, lupus mastitis is seen in patients with a previous diagnosis of systemic or discoid lupus; however, it can also be the initial presentation of lupus in some patients. We report on 2 cases of lupus mastitis where the clinical impression was to rule out malignancy and review the literature to highlight the key clinicopathologic features.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Lupus Mastitis

Kinonen

Gattuso

Reddy

2010

American Journal of Surgical Pathology

View full text Add to dashboard Cite

show abstract

“…Pathologically, IBC is characterized by extensive lympho-vascular invasion and involvement of dermal lymphatics [6][7][8][9][10]. The clinical diagnosis of IBC, however, is often very difficult, since a number of breast and other lesions morphologically simulate IBC [11][12][13]. Although a number of molecules, including carbonic anhydrase IX, epidermal growth factor receptors, transmembrane mucin glycoprotein, Wingless-Type 1 induced secreted protein 3, c-erb-B2, and E-cadherin, are aberrantly expressed in IBC, none of these markers can specifically or reliably identify the IBC cells metastasized to lymph nodes or cells within lymphatic channels [14][15][16][17][18][19].…”

Section: Introductionmentioning

confidence: 99%

BP1, a putative signature marker for inflammatory breast cancer and tumor aggressiveness1

Man

Schwartz

Levine

et al. 2009

CBM

View full text Add to dashboard Cite

Our previous studies revealed that beta protein 1 (BP1) was barely detectable in normal human breasts, but was seen in 21%, 46%, and 81% of hyperplastic, in situ, and invasive breast lesions, respectively. Our current study attempted to assess BP1 expression in inflammatory breast cancer (IBC), a very aggressive subtype of breast cancers characterized by extensive lympho-vascular invasion and involvement of dermal lymphatics. Paraffin-embedded tissue sections from 45 cases of IBC (nine with paired metastatic lymph nodes) and different controls were assayed immunohistochemically for BP1 expression. Positive BP1 immunoreactivities were present in all IBC cases. Strikingly, all cancer cells metastasized to lymph nodes and cells within lymphatic channels were uniformly and strongly immunoreactive to BP1. The percentage of BP1 positive cells and the intensity of BP1 immunostaining in IBC cases were significantly greater than those in non-IBC cases. Our findings suggest that BP1 may possess properties of onco-proteins that promote tumor progression, invasion, and metastasis, representing a putative signature marker for IBC and tumor aggressiveness.

show abstract

“…A literature search using PubMed revealed 30 previously described cases of LM6 9 11–14 in addition to ours, with the findings summarised in tables 1–3.…”

Section: Discussionmentioning

confidence: 74%